Liposomes in the treatment of malignancy: a clinical perspective

Medicine & Life Sciences

• Liposomes 100%
• bis-neodecanoato-1,2-diaminocyclohexaneplatinum(II) 33%
• Neoplasms 32%
• Melanoma 25%
• Pharmaceutical Preparations 22%
• liposomal doxorubicin 21%
• Immunoconjugates 20%
• Phase II Clinical Trials 19%
• Phase III Clinical Trials 18%
• Drug Compounding 18%
• Immunologic Factors 16%
• Therapeutics 16%
• Breast Neoplasms 14%
• Macrophage-Activating Factors 12%
• sialogangliosides 12%
• Pharmacokinetics 11%
• Morus 11%
• Unilamellar Liposomes 10%
• Transition Temperature 10%
• Clinical Trials 10%
• Chills 9%
• Phase Transition 9%
• Butyric Acid 9%
• Cancer Vaccines 9%
• Drug Carriers 9%
• Biological Therapy 9%
• Dactinomycin 8%
• Cardiotoxicity 8%
• Polyethylene Glycols 8%
• Antibodies 8%
• Leukopenia 8%
• Anorexia 8%
• Phosphatidylinositols 8%
• Embolism 7%
• Pulmonary Embolism 7%
• Drug Liberation 7%
• Antineoplastic Agents 7%
• Nude Mice 7%
• Drug-Related Side Effects and Adverse Reactions 7%
• Doxorubicin 7%
• Interferons 7%
• Cisplatin 7%
• Interferon-gamma 6%
• Interleukin-2 6%
• Immunotherapy 6%
• Fear 6%
• Fatigue 6%
• Lymphoma 6%
• Fever 5%
• Hospitalization 5%
• Monoclonal Antibodies 5%
• Direction compound 5%
• Animal Models 5%
• Ligands 5%
• Clinical Studies 5%
• Equipment and Supplies 4%
• Cell Line 4%
• Blood Vessels 4%
• Drug Therapy 4%
• Lung 4%